Gavin Giovannoni

aan alemtuzumab berlin bg12 cladribine daclizumab dextromethorphan disease activity free status disease-activity free fampridine heathrow airport holistic approach interferon beta jcv ms society multiple sclerosis multiple sclerosis; ectrims multtiple sclerosis nabs natalizumab nhs pba pml pml risk stratification profg risk more…

2013 aan alemtuzumab asian ms assisted suicide; multiple sclerosis barts and the london berlin bg12 bg12. alemtuzumab biogen-idec biomarkers biosimilars brain atrophy cannabis cerebrospinal fluid charcot foundation cis cladribine clarity clinical trials cognition commisioners concordance confirm daclizumab define dextromethorphan disease activity free disease activity free status disease progression disease-activity free disease-modifying drugs disease-modifying therapies dmt dmts ectrims elisa employment european charcot foundation extension study falls fampridine fda fda. teva fumaderm gsk heathrow airport holistic approach hospitalizations immunology interferon beta interferon-beta ipmsc jcv lecture notes lumbar puncture medical students milan mri monitoring ms ms frontiers ms society multiple sclerosis multiple sclerosis; ectrims multtiple sclerosis mxa nabs natalizumab neda neurofilaments neuroprotection nhs nmss nuedexta ocbs oracle oracle study patient information sheet pba personalised medicine pml pml risk stratification pregnancy private patient profg progressive disease promise 2010 proximus pseudobulbar affect pseudobulbar palsy psoriasis quinidine research day feedback risk risk management risk stratification rosiglitazone safety safety update sativex scheduling selection study serology services sleep questionnaire stem cells steroids streams survey survey results taste teriflunomide tube map uclp vienna vitamin d …less